Amarin Corp. Plc, a biopharmaceutical company, specializes in developing and commercializing therapeutics aimed at enhancing cardiovascular health, primarily through its lead product, Vascepa. Vascepa, used to lower triglyceride levels in adults with severe hypertriglyceridemia, is distributed mainly to wholesalers and pharmacies.
AMRN filed a patent for "methods of reducing risks of cardiovascular events in subjects with low baseline epa:aa ratio" on Thu, November 10, 2022.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
